HYBRID EVENT: Join us in person in Tokyo, Japan or attend virtually from anywhere.
Chronic Myeloproliferative Neoplasms (MPNs) are a group of rare blood disorders characterized by the excessive production of mature blood cells in the bone marrow. These conditions result from genetic mutations in hematopoietic stem cells, leading to abnormal growth and function of blood cells. The three main types of MPNs include polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF). PV is characterized by an overproduction of red blood cells, ET involves an excess of platelets, and MF is characterized by the replacement of bone marrow with fibrous tissue. Individuals with MPNs may experience a range of symptoms, including fatigue, night sweats, weight loss, and an enlarged spleen. Complications can arise due to abnormal blood cell counts, leading to an increased risk of blood clots, bleeding, and an elevated risk of developing acute leukemia. Management of MPNs aims to control symptoms, prevent complications, and improve the quality of life for affected individuals. Treatment options may include medication, phlebotomy to reduce blood cell counts, and in some cases, stem cell transplantation. Regular monitoring and follow-up are essential for individuals with MPNs to manage their condition effectively and address any emerging complications. Despite ongoing research, there is currently no cure for chronic myeloproliferative neoplasms, highlighting the importance of ongoing medical care and support for individuals living with these rare blood disorders.
